59 related articles for article (PubMed ID: 38652202)
21. PROTACs targeting androgen receptor signaling: potential therapeutic agents for castration-resistant prostate cancer.
Zhang Y; Ming A; Wang J; Chen W; Fang Z
Pharmacol Res; 2024 May; ():107234. PubMed ID: 38815882
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor variation affects prostate cancer progression and drug resistance.
McCrea E; Sissung TM; Price DK; Chau CH; Figg WD
Pharmacol Res; 2016 Dec; 114():152-162. PubMed ID: 27725309
[TBL] [Abstract][Full Text] [Related]
23. Alternative splicing in prostate cancer progression and therapeutic resistance.
Rawat C; Heemers HV
Oncogene; 2024 May; 43(22):1655-1668. PubMed ID: 38658776
[TBL] [Abstract][Full Text] [Related]
24. Splice Variants of Androgen Receptor and Prostate Cancer.
Caffo O; Maines F; Veccia A; Kinspergher S; Galligioni E
Oncol Rev; 2016 Apr; 10(1):297. PubMed ID: 27471583
[TBL] [Abstract][Full Text] [Related]
25. Structure-guided design of a selective inhibitor of the methyltransferase KMT9 with cellular activity.
Wang S; Klein SO; Urban S; Staudt M; Barthes NPF; Willmann D; Bacher J; Sum M; Bauer H; Peng L; Rennar GA; Gratzke C; Schüle KM; Zhang L; Einsle O; Greschik H; MacLeod C; Thomson CG; Jung M; Metzger E; Schüle R
Nat Commun; 2024 Jan; 15(1):43. PubMed ID: 38167811
[TBL] [Abstract][Full Text] [Related]
26. Letter to the Editor regarding the article "A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer: How to choose drugs appropriately?".
Zhou S; Alerasool P; Tsao CK
Crit Rev Oncol Hematol; 2024 May; 199():104383. PubMed ID: 38744416
[No Abstract] [Full Text] [Related]
27. Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer.
Abbasi A; Movahedpour A; Amiri A; Najaf MS; Mostafavi-Pour Z
Curr Mol Med; 2021; 21(4):332-346. PubMed ID: 32881669
[TBL] [Abstract][Full Text] [Related]
28. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.
Coleman DJ; Van Hook K; King CJ; Schwartzman J; Lisac R; Urrutia J; Sehrawat A; Woodward J; Wang NJ; Gulati R; Thomas GV; Beer TM; Gleave M; Korkola JE; Gao L; Heiser LM; Alumkal JJ
Oncotarget; 2016 Jun; 7(26):40690-40703. PubMed ID: 27276681
[TBL] [Abstract][Full Text] [Related]
29. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
30. Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients.
Khan A; Mao Y; Tahreem S; Wei DQ; Wang Y
Int J Biol Macromol; 2022 Oct; 218():856-865. PubMed ID: 35905763
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment.
Kregel S; Wang C; Han X; Xiao L; Fernandez-Salas E; Bawa P; McCollum BL; Wilder-Romans K; Apel IJ; Cao X; Speers C; Wang S; Chinnaiyan AM
Neoplasia; 2020 Feb; 22(2):111-119. PubMed ID: 31931431
[TBL] [Abstract][Full Text] [Related]
32. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ
Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029
[TBL] [Abstract][Full Text] [Related]
33. Developing a Novel Enzalutamide-Resistant Prostate Cancer Model via AR F877L Mutation in LNCaP Cells.
Wang R; Ma S; Xu N; Gan Y; Li P; Zhang J; Zhang Z; Gu Q; Xiang J
Curr Protoc; 2024 Apr; 4(4):e1033. PubMed ID: 38652202
[TBL] [Abstract][Full Text] [Related]
34. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
Graham L; Schweizer MT
Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
